Monday , April 24 2017

From the Editor

April, 2017

  • 22 April

    April 22, 2017


    For many years, we never really gave great concern to the micro- and macrovascular problems in type 2 patients. Most of them were not diagnosed until they were in their late 50’s or early 60’s, and they did not really live long enough to develop severe problems. Now that diabetes ...

    Read More »

Latest Articles

April, 2017

Test Your Knowledge

CV Risk in Patients with Diabetes

There is an antidiabetic medication available on the U.S. market with an indication from the U.S. Food and Drug Administration (FDA) to prevent cardiovascular (CV) disease.


Correct Answer: A. True

Explanation:  In December 2016, the FDA approved a new indication for Jardiance® (empagliflozin) to reduce CV risk in adult patients with type 2 diabetes (T2D) and CV disease. The decision was based on a postmarket clinical trial in which 7000 patients with T2D and CV disease were given empagliflozin vs placebo. Empagliflozin was shown to reduce the risk for CV death compared with placebo when added to standard-of-care therapies for T2D and atherosclerotic CV disease.


US Food and Drug Administration. FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes. Published December 2, 2016.   ADA. Diabetes Care. 2017;40(Suppl 1):S65.  Novo Nordisk. 2016. Package insert for Jardiance®.


More Articles

April, 2017